Plasma Acylation-Stimulating Protein in Coronary Heart Disease Patients
Author:
  • Article
  • | |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • | |
  • Comments
    Abstract:

    Aim To estimate the plasma acylation-stimulating protein (ASP) level in coronary heart disease patients, and to investigate the correlation of plasma ASP with blood lipids. Methods 109 subjects were involved in this study, including 62 coronary heart disease patients and 47 health controls. Enzyme linked immunosorbent assay (ELISA) technique was used to determine the plasma ASP concentration. Blood lipid levels were detected by immune turbidimetry. Results The levels of plasma ASP were increased significantly in coronary heart disease group compared with control group (P< 0.05). Body mass index (BMI), systolic blood pressure, diastolic blood pressure, total cholesterol (TC), triglyceride, low density lipoprotein (LDL) and apolipoprotein B100 (apo B100) of coronary heart disease group are significantly different from the control group ( P< 0.05). Plasma ASP correlated positively with BMI, TC, triglyceride, LDL and apo B100 (respectively r = 0.42, P< 0.01; r = 0.36, p<0.01; r = 0.20, p<0.05; r = 0.31, p<0.05; r = 0.45, p<0.01). Conclusion Plasma ASP takes part in the generation of the disorder of lipid metabolism in coronary heart disease. ASP could be used as a new indicator to evaluate the risk to develop cardiovascular disease.

    Reference
    Related
    Cited by
Get Citation

LU Hui-Ling, WANG Hong-Wei, ZHAO Hua-Yue,,ON Han-Hua. Plasma Acylation-Stimulating Protein in Coronary Heart Disease Patients[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2003,11(7):629-631.

Copy
Related Videos

Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:May 30,2003
  • Revised:November 05,2003
Article QR Code